ATI-2138 is under clinical development by Aclaris Therapeutics and currently in Phase I for Psoriasis. According to GlobalData, Phase I drugs for Psoriasis have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ATI-2138’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ATI-2138 is under development for the treatment of psoriasis, inflammatory dermatoses, arthritis, inflammatory bowel disease and ulcerative colitis. It is administered through oral route. The drug candidate is an ITK/TXK/JAK3 inhibitor. It is developed based on KINect, drug discovery platform.
Aclaris Therapeutics overview
Aclaris Therapeutics is bio-pharmaceutical company focused on identifying, developing and commercializing small molecule therapies for immuno-inflammatory conditions. Its lead product, ESKATA is a proprietary formulation of high-concentration hydrogen peroxide topical solution prescribed for the treatment of raised seborrheic keratosis (SK). The company’s pipeline products include A-101, ATI-1777-oral JAK 1/3 inhibitor, ATI-501, ATI-450-oral MK2 pathway inhibitor, soft JAK inhibitor, ITK oral anti-IL17 and ITK topical anti-IL17.Aclaris Therapeutics’ pipeline products are used for the treatment of common warts, alopecia areata, androgenetic alopecia, psoriasis, arthritis, gangrenosum, inflammatory bowel disease and atopic dermatitis. The company also develops investigational drugs to treat skin and hair conditions. Aclaris Therapeutics is headquartered in Wayne, Pennsylvania, the US.
For a complete picture of ATI-2138’s drug-specific PTSR and LoA scores, buy the report here.